1. Home
  2. LNTH

LNTH

Lantheus Holdings Inc.

Logo Lantheus Holdings Inc.

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

as 04-24-2024 1:30pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Founded: 1956 Country:
N/A
Employees: N/A City: NORTH BILLERICA
Market Cap: 4.4B IPO Year: 2015
Target Price: $101.00 AVG Volume (30 days): 924.3K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 4.65 EPS Growth: 1062.50
52 Week Low/High: $50.20 - $100.85 Next Earning Date: 01-01-0001
Revenue: $1,296,429,000 Revenue Growth: 38.65%
Revenue Growth (this year): 12.69% Revenue Growth (next year): 7.19%

Share on Social Networks: